The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases.
Lin Zhou
Research Funding - Zhejiang Beta Pharma
Jiazhuo He
Research Funding - Zhejiang Beta Pharma
Weijie Xiong
Research Funding - Zhejiang Beta Pharma
Qin Yu
No relevant relationships to disclose
Jin Xiang
No relevant relationships to disclose
Maozhi Liang
No relevant relationships to disclose
Yongmei Liu
No relevant relationships to disclose
Zhenyu Ding
No relevant relationships to disclose
Youling Gong
No relevant relationships to disclose
Meijuan Huang
No relevant relationships to disclose
Jiang Zhu
No relevant relationships to disclose
Lu Li
No relevant relationships to disclose
Yongsheng Wang
No relevant relationships to disclose
Mei Hou
No relevant relationships to disclose
Li Ren
No relevant relationships to disclose
You Lu
Research Funding - Zhejiang Beta Pharma